Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. by BALDANZI G et al.
ORIGINAL PAPER
Activation of diacylglycerol kinase a is required for VEGF-induced
angiogenic signaling in vitro
Gianluca Baldanzi1,4, Stefania Mitola2,4, Santina Cutrupi1, Nicoletta Filigheddu1,
Wim J van Blitterswijk3, Fabiola Sinigaglia1, Federico Bussolino2,4
and Andrea Graziani*,1,4
1Department of Medical Sciences, University Amedeo Avogadro of Piemonte Orientale, v. Solaroli 17, 28100, Novara, Italy; 2Institute
for Cancer Research and Treatment (IRCC) and Department of Oncological Sciences, University of Torino, Italy; 3Division of
Cellular Biochemistry at the Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Vascular endothelial growth factor-A (VEGF-A) pro-
motes angiogenesis by stimulating migration, proliferation
and organization of endothelium, through the activation of
signaling pathways involving Src tyrosine kinase. As we
had previously shown that Src-mediated activation of
diacylglycerol kinase-a (Dgk-a) is required for hepato-
cytes growth factor-stimulated cell migration, we asked
whether Dgk-a is involved in the transduction of
angiogenic signaling. In PAE-KDR cells, an endothelial-
derived cell line expressing VEGFR-2, VEGF-A165,
stimulates the enzymatic activity of Dgk-a: activation is
inhibited by R59949, an isoform-speciﬁc Dgk inhibitor,
and is dependent on Src tyrosine kinase, with which Dgk-a
forms a complex. Conversely in HUVEC, VEGF-A165-
induced activation of Dgk is only partially sensitive to
R59949, suggesting that also other isoforms may be
activated, albeit still dependent on Src tyrosine kinase.
Speciﬁc inhibition of Dgk-a, obtained in both cells by
R59949 and in PAE-KDR by expression of Dgk-a
dominant-negative mutant, impairs VEGF-A165-depen-
dent chemotaxis, proliferation and in vitro angiogenesis.
In addition, in HUVEC, speciﬁc downregulation of Dgk-a
by siRNA impairs in vitro angiogenesis on matrigel,
further suggesting the requirement for Dgk-a in angio-
genic signaling in HUVEC. Thus, we propose that
activation of Dgk-a generates a signal essential for both
proliferative and migratory response to VEGF-A165,
suggesting that it may constitute a novel pharmacological
target for angiogenesis control.
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Introduction
Tumor growth and metastasis to distant organs, as well
as revascularization of ischemic tissues and female cycle
are dependent on angiogenesis, the formation of new
blood vessels by branching from pre-existing ones
(Folkman, 1972; Carmeliet and Jain, 2000). Angiogen-
esis is promoted by angiogenic factors secreted by
hypoxic tissues, such as vascular endothelial growth
factor (VEGF), basic ﬁbroblast growth factor (bFGF)
and hepatocytes growth factor (HGF) (Bussolino et al.,
1992; Matsumoto and Claesson-Welsh, 2001). In
particular, VEGF-A, whose receptors are mostly ex-
pressed on endothelial cells, plays a crucial role in the
angiogenesis in vivo (Folkman, 1972; Carmeliet and
Jain, 2000; Matsumoto and Claesson-Welsh, 2001).
Because antiangiogenic therapy is currently believed to
be a promising approach to cancer treatment (Folkman,
1972; Carmeliet and Jain, 2000; Matsumoto and
Claesson-Welsh, 2001), the identiﬁcation of new pro-
teins involved in the biochemical mechanisms transdu-
cing angiogenic extracellular signals would provide
novel biochemical targets for pharmacological interven-
tion. VEGF-A stimulates angiogenesis by activating
several signaling pathways in a spatially and timely
coordinate manner, leading to endothelial cells migra-
tion, proliferation and organization in tubular structures
(reviewed in Matsumoto and Claesson-Welsh, 2001).
Among the numerous pathways activated, the genera-
tion of phosphatidylinositol(4,5)bis-phosphate
(PI(4,5)P2)-derived second messengers plays a crucial
role in VEGF-A angiogenic signaling. Indeed,
VEGF-A-induced angiogenic signaling requires both
phosphorylation and hydrolysis of PI(4,5)P2, mediated,
respectively, by phosphatidylinositol 3-kinase (PI 3-
kinase) and phospholipase C-g (PLC-g to generate
phosphatidylinositol(3,4,5)tris-phosphate (PI(3,4,5)P3)
and diacylglycerol (DG). While PI(3,4,5)P3 is required
for activation of Akt, which mediates VEGF-A-induced
survival signaling (Gerber et al., 1998), DG is required
for activation of PKC-a, which mediates VEGF-A-
induced proliferative and chemotactic signaling (Wellner
et al., 1999; Matsumoto and Claesson-Welsh, 2001).
Diacylglycerol kinase (Dgk) enzymes phosphorylate
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diacylglycerol to generate phosphatidic acid (PA),
regulating in a reciprocal manner the level of two lipid
second messengers (Topham and Prescott, 1999). Thus
Dgk enzymes may act both as terminators of DG-
mediated signaling and as activators of PA-mediated
signals. Indeed, activation of Dgk enzymes has been
reported to downregulate DG-regulated enzymes such
as PKCs and Ras GTP releasing proteins (RasGRP),
respectively, in platelets and T cells (De Chaffoy de
Courcelles et al., 1989; Jones et al., 2002; Zhong et al.,
2002). On the other hand, activation of Dgk-a has been
reported to convey proliferative and motility signals,
respectively, in IL-2-stimulated T lymphocytes and in
HGF-stimulated endothelial cells (Flores et al., 1996;
Cutrupi et al., 2000). In addition, generation of PA
through phospholipase D (PLD)-mediated hydrolysis of
phospholipid is required for vescicular trafﬁcking,
lamellipodia, cell migration and proliferation in differ-
ent cellular systems (English, 1996; Honda et al., 1999;
O’Luanaigh et al., 2002).
To date, nine distinct Dgk isoforms have been cloned
in mammalians, encoding soluble proteins that rever-
sibly associate to the membrane or to the nucleus
(reviewed in Topham and Prescott, 1999). All isoforms
share a highly conserved catalytic domain, preceded by
at least two Zn ﬁngers, homologous to the C1 domain of
PKCs. Five different families have been deﬁned accord-
ing to the different N-terminal regulatory domains.
Class I Dgk, comprising a-, b- and g-isoforms, shares a
common N-terminal autoinhibitory motif and a pair of
EF-hand calcium-binding domains preceding the Zn
ﬁngers. Dgk-a is abundant in T lymphocytes, but is also
expressed in endothelial and epithelial cells, ﬁbroblasts
and oligodendrocytes (Schaap et al. 1990; Cutrupi et al.,
2000; data not shown). The biological functions and
biochemical regulation of Dgk enzymes are currently
under investigation (reviewed in van Blitterswijk and
Houssa, 2000). We have previously shown that upon
HGF stimulation of a porcine aortic cell line (PAE),
Dgk-a is activated and associates in a complex with Src.
In addition, we have also shown that Dgk-a is regulated
by tyrosine phosphorylation and that its activation
requires Src tyrosine kinase activity (Cutrupi et al.,
2000). Speciﬁc inhibition of Dgk-a, either through
expression of a dominant-negative mutant or by cell
treatment with R59949, a pharmacological inhibitor,
impairs HGF-induced chemotaxis of endothelial cells
(Cutrupi et al., 2000) and IL-2-induced proliferation of
T lymphocytes (Flores et al., 1996).
Thus, based on these data and on the absolute
requirement for Src tyrosine kinase activity in VEGF-
A-induced proliferation and motility of endothelial cells
(Abu-Ghazaleh et al., 2001), we set to investigate the
role of Dgk-a in VEGF-A signaling in PAE cells
expressing VEGFR-2 (PAE-KDR) and in human
umbilical vein endothelial cells (HUVEC). Herein we
report that (i) VEGF-A165 stimulates Dgk-a activity in
an Src-dependent manner and, at least in PAE-KDR,
induces the formation of a Dgk-a/Src complex; (ii) both
pharmacological inhibition of Dgk-a in both cells and
expression of Dgk-a dominant-negative mutant in PAE-
KDR impair VEGF-A165-induced chemotaxis and pro-
liferation, as well as in vitro formation of tubule
structures in matrigel; (iii) speciﬁc downregulation of
Dgk-a by siRNA in HUVEC impairs in vitro formation
of tubule structures in matrigel. These are the ﬁrst
evidences indicating the involvement of Dgk-a in
VEGF-A signal transduction, providing the ﬁrst de-
monstration that Dgk-a activation is necessary for the
VEGF-A-triggered angiogenic program. Furthermore,
these data indicate Dgk-a as a promising novel
pharmacological target for angiogenesis control.
Results
VEGF-A165 activates Dgk-a
Stimulation of VEGFR-2 tyrosine kinase activity
mediates the activation of the angiogenetic response
induced by VEGF-A in HUVEC and PAE-KDR cells
(Waltenberger et al., 1994; Matsumoto and Claesson-
Welsh, 2001). Thus, we have measured Dgk activity
in vitro in cell homogenates obtained from either control
or VEGF-A165-stimulated PAE, PAE-KDR and HU-
VEC. Dgk activity was measured in vitro as phosphor-
ylation of exogenous DG in the presence of radiolabeled
ATP. The activity of homogenates obtained from PAE-
KDR and HUVEC stimulated with VEGF-A165 was
twofold higher than from untreated control cells
(Figure 1a). The activation was sustained for at least
1 h (Figure 1b) and dependent on VEGF concentration
(data not shown). On the other hand, Dgk activity from
PAE cells, which do not express VEGFR-2 at signiﬁcant
Figure 1 VEGF-A165 activates DGK in PAE-KDR and HUVEC.
(a) Dgk activity assayed on whole-cell homogenates from either
control or VEGF-A165 (10 ng/ml for 10min)-stimulated quiescent
PAE, PAE-KDR and HUVEC cells. (b) Dgk-a protein assayed by
Western blot with anti-Dgk-a antibodies in whole-cell extracts
from PAE, PAE-KDR and HUVEC. (c) Time course of Dgk
activation in VEGF-A165-stimulated (VEGF-A165 50 ng/ml) PAE-
KDR cells
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levels, was not increased upon VEGF-A165 stimulation
(Figure 1a). Intriguingly, even in the absence of
exogenous VEGF-A165, basal Dgk activity from PAE-
KDR was much higher than from PAE cells, suggesting
that the sole expression of VEGFR-2, putatively
through an autocrine loop, is sufﬁcient to generate a
signal that upregulates Dgk activity. Indeed, PAE and
PAE-KDR express VEGF, as measured by RT–PCR,
and both basal ERK-1/2 and Src activities are upregu-
lated in unstimulated PAE-KDR cells compared with
PAE cells (data not shown).
However, these experiments, which clearly indicate
that VEGF-A165 stimulates a Dgk activity, do not allow
to establish which of the different Dgk isoforms are
activated upon VEGF-A165 stimulation of these cells.
Dgk-a is expressed at similar levels in PAE and PAE-
KDR cells, as measured by Western blot with Dgk-a
antibodies, while in HUVEC its expression is signiﬁ-
cantly lower (Figure 1c). Thus in order to verify whether
Dgk-a is regulated by VEGF-A165, we assayed in vitro
the Dgk activity in anti-Dgk-a immunoprecipitates from
lysates of PAE-KDR cells, either control or VEGF-A165
stimulated. Indeed, Dgk activity in anti-Dgk-a immu-
noprecipitates from VEGF-A165-stimulated cells was
higher than from unstimulated cells, while the amount
of Dgk-a protein immunoprecipitated did not change
(Figure 2a). VEGF-induced activation of Dgk-a was
sustained for at least 60min (Figure 2b), and was
dependent on VEGF concentration (Figure 2c). Mock
immunoprecipitates carried out in the absence of anti-
Dgk-a antibodies did not contain either Dgk-a protein
or activity.
In order to further characterize the Dgk activity
stimulated by VEGF-A165 in PAE-KDR cells and
HUVEC cells, we have veriﬁed whether it is inhibited
in vitro by R59949, a class I Dgk-speciﬁc inhibitor with a
strong preference for the a- and b-isoform rather than
the g-isoform (Kai et al., 1994), whose effects on
tyrosine kinase signaling in PAE cells are reverted by
overexpression of Dgk-a (Cutrupi et al., 2000). In
endothelial cells, R59949 cell treatment did not affect
both VEGFR-2 tyrosine phosphorylation (Figure 3a)
and cell viability as measured by Trypan blue
(Figure 3b). In vitro, 1 mM R59949 inhibited completely
both basal and VEGF-induced Dgk activity assayed in
PAE-KDR cell homogenates (Figure 3c). Conversely,
R59949, even at 10 mM, inhibited only part of both basal
and VEGF-stimulated Dgk activity assayed in HUVEC
homogenates (Figure 3c), suggesting that in these cells
VEGF-A165 may stimulate other Dgk isoforms also that
are less sensitive to R59949.
Expression of a dominant-negative mutant of Dgk-a
impairs VEGF-A165-induced in vitro angiogenesis
To further investigate the involvement of Dgk-a VEGF
signaling, we expressed a catalytic inactive mutant of
Dgk-a Dgk-a-K), which acts as dominant negative in
PAE cells (Cutrupi et al., 2000). PAE-KDR cells were
infected with PINCOS retrovirus containing myc-tagged
Dgk-a-K, obtained as described previously (Cutrupi
et al., 2000). The efﬁciency of infection, measured as
green ﬂuorescent protein (GFP) expression by FACS
analysis, was about 70% (data not shown), while the
expression of myc-tagged Dgk-a, either wt or K, was
about two to threefold the expression of endogenous
Dgk-a (data not shown). Thus the PAE-KDR-PINCOS
cell lines, containing either empty vector, Dgk-a-wt or
Figure 2 VEGF-A165 activates Dgk-a. (a) Dgk-a activity (upper
panel) and protein (lower panel) assayed on anti-Dgk-a immuno-
precipitates from lysates of either control or VEGF-A165 (10 ng/ml
for 10min)-stimulated PAE-KDR cells. Time course (b) and VEGF
concentration dependence (c) of Dgk-a activation, assayed in anti-
Dgk-a immunoprecipitates from PAE-KDR stimulated, respec-
tively, with 50 ng/ml VEGF-A165 and upon 15min stimulation
Figure 3 VEGF-A165-stimulated Dgk is sensitive to R59949. (a)
Antiphosphotyrosine (upper panel) and anti-VEGFR-2 (lower
panel) Western blot of anti-VEGFR-2 immunoprecipitates from
either unstimulated or VEGF-A165 (10 ng/ml for 10min)-stimu-
lated HUVEC, pretreated for 15min with either R59949 1mM or
vehicle. (b) Cell viability, quantiﬁed by Trypan blue exclusion, of
PAE-KDR cells maintained in the presence (10%) or absence of
FCS and R59949 (1mM) for the time indicated. (c) Dgk activity
assayed in the presence of the indicated concentrations of R59949
on whole-cell homogenates from either control or VEGF-A165
(10 ng/ml for 10min)-stimulated quiescent PAE-KDR and HU-
VEC cells (data are mean7s.e.m. of ﬁve independent experiments
normalized for control, 1t-test vs control, *t-test vs VEGF-A165,
Po0.05)
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dominant-negative mutant, were assayed in a chemo-
taxis assay on a collagen I matrix. The expression of
Dgk-a dominant-negative mutant in PAE-KDR signiﬁ-
cantly inhibited VEGF-A165-induced cell migration
(Figure 4a), while it did not affect cell migration induced
by fetal calf serum (FCS) (data not shown). Conversely,
the expression of Dgk-a-wt enhanced the migratory
response of PAE-KDR cells to VEGF by about twofold,
although the difference was not statistically signiﬁcant
(Figure 4a).
The same cell lines were also assayed for VEGF-A165-
induced DNA synthesis. The expression of Dgk-a
dominant-negative mutant reduced VEGF-A165-induced
DNA synthesis of PAE-KDR, while the expression of
wt Dgk-a did not affect DNA synthesis of these cells
upon VEGF-A165 treatment (Figure 4b). Similar to the
cell migration assay, the expression of Dgk-a dominant-
negative mutant did not affect FCS-induced DNA
synthesis of PAE-KDR cells (data not shown).
To further investigate the involvement of Dgk-a in
VEGF-A165 angiogenic signaling, we have veriﬁed
whether the expression of Dgk dominant-negative
mutant impairs the ability of endothelial cells to form
tubular-like structures on matrigel, a mixture of
laminin-rich basement membrane enriched in growth
factors. In this assay, which is currently used to test in
vitro pro- or antiangiogenic properties of molecules,
endothelial cells are stimulated to migrate and to
organize themselves in a chord structure network
(Benelli and Albini, 1999). PAE-KDR cells infected
with empty PINCOS vector or expressing Dgk-wt once
plated on matrigel in the presence of VEGF-A165 (10 ng/
ml) elongate and connect through chord-like structures
to generate a complex network. However, PAE-KDR
expressing Dgk-K, although still viable, fail to connect
and to differentiate in chord-like structures, resulting in
Figure 4 Expression of Dgk-a dominant negative inhibits VEGF-
A165-induced in vitro angiogenetic signaling. Quiescent PAE-KDR
infected with either empty or Myc-Dgk-a-wt or Myc-Dgk-a-K
virus were assayed for chemotaxis (a), DNA synthesis (b) and
network formation on matrigel (c) as follows. (a) Cells were plated
in a modiﬁed Boyden chamber coated with collagen I and induced
to migrate with 20 ng/ml of VEGF-A165 for 6 h. Data are shown as
fold increase over control; each value is the mean 7s.e. of six
points (*t-test, Po0.01%). (b) Cells were cultured in 96-well plates
in the presence or absence of VEGF-A165 (10 ng/ml, absence of
serum, 24 h). BrdU incorporation assay was carried out as
described. Data are shown as fold increase over control; each
value is the mean7s.e. of eight points (*t-test, Po0.01%). (c) Cells
were plated on growth factor-rich matrigel, and stimulated with
VEGF-A165 (25 ng/ml) for 24 h, in the presence or absence of 1 mM
R59949. Cells were photographed with contrast phase microscopy
Figure 5 R59949 5 R59949 inhibits VEGF-A-induced cell motility
and proliferation of PAE-KDR and HUVEC. Quiescent PAE-
KDR (a,c) and HUVEC (b,d) were assayed for chemotaxis (a,b)
and DNA synthesis (c,d) as follows: quiescent PAE-KDR (a) or
HUVEC (b) were plated in a modiﬁed Boyden chamber coated with
gelatin and induced to migrate in the presence of either 10 ng/ml (a)
or 20 ng/ml (b) of VEGF-A165 or 20% FCS for 6 h, in the presence
or absence of 1mM R59949. Each value is the mean 7s.e. of
triplicates (1t-test vs control, *t-test vs VEGF-A165 stimulated,
Po0.01%). Quiescent PAE-KDR (c) or HUVEC (d) were cultured
in 96-wells plates for either 24 h (c) or 48 h (d) with or without
VEGF-A165 (c) 25 ng/ml in the absence of serum, (d) 10 ng/ml, 2%
serum) or 10% FCS and in the presence or absence of R59949 at
the indicated concentrations. BrdU incorporation was assayed as
described. Each value is the mean 7s.e. of eight points (1t-test vs
control, *t-test vs VEGF-A165 stimulated, Po0.01%)
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a severe impairment of the formation of the character-
istic network (Figure 4c).
Pharmacological inhibition of Dgk-a impairs in vitro
VEGF-A165-induced angiogenesis
Based on the sensitivity of Dgk-a to the inhibition by
micromolar concentrations of R59949, we assayed its
ability to inhibit VEGF-A165-induced biological re-
sponses in both HUVEC and PAE-KDR cells. Indeed
we had previously shown that R59949 inhibition of
HGF-induced chemotaxis was completely reverted by
overexpression of Dgk-a, providing a strong indication
for the speciﬁcity of R59949-induced inhibition (Cutrupi
et al., 2000).
In the presence of 1 mM R59949, VEGF-A165-stimu-
lated cell migration was inhibited by about 50 and 60%,
respectively, in PAE-KDR and HUVEC, while basal
cell motility of unstimulated cells was not signiﬁcantly
affected. However, in both PAE-KDR and HUVEC,
R59949 did not inhibit cell migration induced by serum,
suggesting that Dgk-a stands in the signaling pathway
conveying signals speciﬁcally from the VEGFR-2 to the
cell motility machinery (Figure 5a and b).
We then investigated the ability of R59949 to inhibit
VEGF-A165-induced DNA synthesis in both PAE-KDR
and HUVEC. In serum-starved PAE-KDR, VEGF-A165
induced a twofold increase of DNA synthesis, which was
completely abolished in the presence of 1 mM R59949
(Figure 5c). In HUVEC cultured in 2% FCS, VEGF-
A165 stimulates DNA synthesis, which was inhibited by
R59949 at concentrations equal or higher than 5 mM
(Figure 5d). The reduced ability of R59949 to inhibit
DNA synthesis in HUVEC may depend on serum
sequestration of R59949 (De Chaffoy de Courcelles
et al., 1989), although the involvement of other Dgk
isoforms, less sensitive to the inhibitor (Jiang et al.,
2000), could not be ruled out.
In addition, we have assayed the ability of R59949 to
inhibit tubular-like structure formation on matrigel both
by HUVEC and PAE-KDR-PINCOS. In the presence
of 1 mM R59949, both PAE-KDR-PINCOS and HU-
VEC, although still viable, fail to connect and to
differentiate in chord-like structures, resulting in a
severe impairment of the formation of the characteristic
complex network (Figures 4c, 6a and b). Cell viability in
the presence of R59949 was veriﬁed by three distinct
assays, Trypan blue, calcein-AM and MTT, reﬂecting
three different cellular functions, respectively membrane
impermeability, cytoplasmic esterase activity and mito-
chondrial respiratory chain activity (Poole et al., 1993;
Baldanzi et al., 2002). R59949 treatment of HUVEC did
not affect their viability as measured by calcein-AM and
MTT (Figure 6a and b), while drug treatement of PAE-
KDR cells did not affect cell viability as measured by
Trypan blue and MTT (Figure3b and data not shown).
Interestingly, the speciﬁcity of R59949 in impairing
angiogenic signaling through inhibition of Dgk-a is
further suggested by the observation that in PAE-KDR
overexpression of Dgk-wt reverts signiﬁcantly the
inhibition of chord-like formation on matrigel
(Figure 4c). This ﬁnding is consistent with the reported
ability of Dgk-a overexpression to revert the inhibition
of HGF-induced chemotaxis exerted by R59949
(Cutrupi et al., 2000).
In addition, we have also veriﬁed whether R59949
impairs VEGF signaling through downregulation of
VEGFR-2 tyrosine phosphorylation. However,
VEGFR-2 tyrosine phosphorylation, as detected by
antiphosphotyrosine Western blot of anti-VEGFR-2
immunoprecipitates, was not affected by cell treatment
with 1 mM R59949 in VEGF-stimulated HUVEC
(Figure 3a).
Figure 6 Downregulation of Dgk-a by RNA interference or
R59949 treatment inhibits VEGF-A165-induced in vitro angiogen-
esis in HUVEC. (a) HUVEC were plated on a growth factor rich
matrigel and stimulated with VEGF-A165 (25 ng/ml) for 24 h in the
presence or absence of 1 mM R59949. Cells were loaded with
Calcein-AM ﬂuorescent viability dye and photographed with
contrast phase microscopy (upper panel) and green ﬂuorescence
(lower panel). (b) siRNA-transfected HUVEC were plated at 48 h
following transfection on a growth factor rich matrigel for 24 h in
the presence or absence of 1 mM R59949. Following image
acquisition at contrast phase microscopy (left), cells were labeled
with MTT vital dye and photographed with bright ﬁeld microscopy
(right). (c) siRNA-transfected HUVEC were homogenized, at 48 h
from transfection, and their Dgk-a content was assayed by Western
blot with anti-Dgk-a antibodies. (d) Cell death, quantiﬁed by
Trypan blue exclusion assay, of siRNA-transfected HUVEC, 70 h
following transfection
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Downregulation of Dgk-a expression by RNA
interference impairs HUVEC endothelial cell
organization on matrigel
In order to provide further evidence that Dgk-a is
involved in VEGF angiogenic signaling in HUVEC, we
synthesized three single interfering RNAs for the Dgk-a
transcript designed with Cenix algorithm, which did not
overlap with any other known transcript from the
human genome. Transfection of HUVEC cells with any
of the three interfering RNAs lowers but does not
abolish the expression of Dgk-a, as detected by Western
blot on whole-cell lysates (Figure 6c). Transfection with
the three interfering RNAs impairs the formation of
chord-like structures on matrigel with efﬁcacy similar to
that obtained with 1 mM R59949 cell treatment. Con-
versely, transfection with a scrambled siRNA, which
does not overlap with any known transcript, did not
affect chord-like formation. In addition, downregula-
tion of Dgk-a expression did not affect cell viability of
HUVEC, as measured by Trypan blue exclusion
(Figure 6d) and MTT (Figure 6b).
In summary, these data indicate that either inhibition
of Dgk-a catalytic activity by both expression of
dominant-negative mutant or cell treatment with a
speciﬁc inhibitor, either downregulation of its expres-
sion by interfering RNA, severely impair the ability of
endothelial cells to migrate, proliferate and organize as
chord-like networks, providing further support to the
claim that catalytic function of Dgk-a is required for the
transduction of VEGF-A165 angiogenic signal.
VEGF-A165-induced activation of Dgk-a is mediated
by Src
Overall, these data demonstrate that VEGF-induced
activation Dgk-a is required for VEGF angiogenic
signaling in endothelial cells. We had previously shown
that activation of Dgk-a by HGF is mediated by Src
(Cutrupi et al., 2000), whose activation is also required
for VEGF-A165-induced cell motility, proliferation and
increase of permeability (Abu-Ghazaleh et al., 2001;
Eliceiri et al., 2002). Thus, we have explored the
hypothesis that Dgk-a may stand as a downstream
target of Src in VEGF-A signaling. Src tyrosine kinase
activity was inhibited by pretreating both PAE-KDR
and HUVEC, respectively, with 5 mM PP2 and PP1. At
these concentrations, either PP1 or PP2 does not affect
VEGFR-2 tyrosine kinase activity (Figure7b and data
not shown) (Waltenberger et al., 1999; Abu-Ghazaleh
et al., 2001). Inhibition of Src tyrosine kinase activity
completely abrogated the stimulation of total Dgk
activity induced by VEGF-A165, demonstrating that
Src mediates the activation of VEGF-A165-induced
stimulation of Dgk in both PAE-KDR and HUVEC
(Figure 7a).
Then we investigated whether VEGF-A165 induces the
formation of a Dgk-a/Src complex, by assaying Dgk
activity co-puriﬁed with Src in anti-Src immunoprecipi-
tates from either control or VEGF-A165-stimulated
PAE-KDR cells. Indeed, Dgk activity in anti-Src
immunocomplexes from stimulated cells was higher
than from control cells (Figure 8a, upper panel), while
mock immunoprecipitates from VEGF-A165-stimulated
cells did not contain any Src protein and Dgk activity.
No Dgk-a protein could be detected by Western blot in
anti-Src immunoprecipitates, suggesting that the stoi-
chiometry of Dgk-a association to Src is very low, below
the level of sensitivity of the Dgk-a antibodies (data not
shown). Indeed even upon HGF stimulation of PAE,
only endogenous Dgk activity, but no endogenous Dgk-
a protein, could be detected in a complex with Src
(Cutrupi et al., 2000).
Thus in order to provide a more conclusive evidence
for the formation of the complex between the two
proteins, we have assayed the ability of myc-tagged
Dgk-a to co-purify with Src in anti-Src immunopreci-
pitates. Myc-tagged Dgk-a was expressed in PAE-KDR
cells by infection with PINCOS retrovirus containing
myc-tagged Dgk-a, obtained as described previously
(Cutrupi et al., 2000). Indeed in infected cells more myc-
Dgk-a was detected by Western blot of anti-Src
immunoprecipitates obtained from VEGF-A165-stimu-
lated rather than unstimulated cells (Figure 5b, upper
panel). The amount of immunoprecipitated Src protein
was not affected by VEGF-A165 stimulation, while no
Figure 7 Src kinase activity is required for VEGF-A165-induced
activation of Dgk. (a) Dgk activity assayed in homogenates from
either control or VEGF-A165 (10 ng/ml for 10min)-stimulated
quiescent PAE-KDR or HUVEC cells, pretreated for 15min with
either vehicle or with 5mM PP2 or PP1 respectively (data are mean
7s.e.m. of ﬁve independent experiments normalized for control, 1t-
test vs control, *t-test vs VEGF-A165, Po0.05). (b) Antipho-
sphotyrosine (upper panel) and anti-VEGFR-2 (lower panel)
Western blot of anti-VEGFR-2 immunoprecipitates obtained from
cell lysates of either control or VEGF-A165 (10 ng/ml for 10min)-
stimulated quiescent HUVEC, pretreated with either vehicle or
5 mM PP2
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complex formation was observed in anti-Src immuno-
precipitates from PAE-KDR cells infected with empty
vector (Figure 8b, upper panel). In addition, we have
been able the observe the formation of the Src/Dgk-a
complex with endogenous proteins, by detecting Src
protein in anti-Dgk-a immunoprecipitates from VEGF-
A165-stimulated but not unstimulated PAE-KDR cells
(Figure 8c).
In summary, these data suggest that Src tyrosine
kinase mediates the activation of Dgk by VEGF in both
PAE-KDR and HUVEC. In addition, VEGF induces
the formation of an Src/Dgk-a complex in PAE-KDR,
while in the HUVEC the paucity of Dgk-a expression
impairs to address the issue. Although we had pre-
viously shown that Dgk-a can be regulated by tyrosine
phosphorylation, no tyrosine phosphorylation of Dgk-a
could be detected upon VEGF-A165 stimulation, as well
as upon HGF stimulation (Cutrupi et al., 2000).
No Dgk activity or protein, either endogenous or
myc-tagged, was detectable in anti-VEGFR-2 immuno-
precipitates (data not shown). Consistent with similar
data obtained with HGF-R, these data suggest that
Dgk-a does not form a stable complex with activated
tyrosine kinase receptors (Cutrupi et al., 2000).
Discussion
Angiogenesis is a complex phenomenon required for
embryonic development, wound healing, female cycle,
solid tumor growth and revascularization of ischemic
tissues (Matsumoto and Claesson-Welsh, 2001). Upon
exposure to angiogenic factors, such as FGF, VEGF-A
and HGF, endothelial cells lining blood vessels are
activated in a spatially and timely coordinated manner
to degrade the vessel basement membrane, invade the
extracellular matrix according a chemotactic gradient,
proliferate and differentiate to form a new lumen-
containing vessel (Matsumoto and Claesson-Welsh,
2001; Gerhardt et al., 2003). Although the signaling
pathways involved in the transduction of angiogenic
stimuli have been extensively investigated, the complete
picture of such signaling network is still missing.
We had previously shown that Dgk-a, which phos-
phorylates DG to PA, is activated by HGF through an
Src-mediated mechanism, and is required for HGF-
stimulated cell movement in a porcine aortic-derived cell
line, raising the hypothesis that it may be involved in the
transduction of the angiogenic signaling (Cutrupi et al.,
2000). However, in order to provide more compelling
evidence for the requirement of Dgk-a in the transduc-
tion of angiogenic signaling, we have investigated the
role of Dgk-a in the signal transduction of VEGF-A, the
major angiogenic factor in vivo, in both HUVEC
primary endothelial cells and in PAE-KDR cells,
an endothelial-derived cell line stably expressing
VEGFR-2.
Herein we showed that VEGF-A165 stimulates Dgk
activity in endothelial cells. In PAE-KDR cells, by
assaying Dgk activity in anti-Dgk-a immunoprecipi-
tates, we provided compelling evidence that Dgk-a
isoform is activated by VEGF. In addition, most of
the total Dgk activity assayed from PAE-KDR whole-
cell homogenates is inhibited in vitro by R59949, which
inhibits selectively class-I Dgk enzymes, that is, the a-, b-
and g- isoforms, while it does not affect the activity of
other Dgk isoforms (Jiang et al. 2000), as well as the
activity of other lipid and protein kinases (De Chaffoy
de Courcelles et al., 1989; Cutrupi et al., 2000). The
ﬁnding that overexpression of wt Dgk-a reverts the
ability of R59949 to impair HGF-induced cell move-
ment and network organization on matrigel, respec-
tively, in PAE and PAE-KDR cells provides further
support to the selectivity of R59949 for Dgk-a (Cutrupi
et al., 2000; Figure 4c). Conversely, in HUVEC, which
express lower levels of Dgk-a than PAE-KDR, VEGF-
stimulated Dgk activity is only partially inhibited by
R59949, suggesting that also R59949-resistant Dgk
activities are activated by VEGF.
In order to investigate whether Dgk-a plays a role in
VEGF angiogenic signaling, we have inhibited it by
three independent strategies, that is, pharmacological
inhibition with R59949 in both PAE-KDR and HU-
VEC, expression of a Dgk-a dominant-negative mutant
in PAE-KDR cells and speciﬁc downregulation of Dgk-
a expression by RNA interference in HUVEC. In vitro,
the ability of endothelial cells to move toward a
Figure 8 Dgk-a protein and activity are associated with Src in
VEGF-A165-stimulated cells. (a) Dgk enzymatic activity (upper
panel) and Western blot of Src protein (lower panel) assayed in
anti-Src immunoprecipitates obtained from lysates of either control
or VEGF-A165 (50 ng/ml for 10min)-stimulated quiescent PAE-
KDR cells. (b) Myc-Dgk protein (upper panel) and Src protein
(lower panel) assayed by Western blot, respectively, with anti-myc
and anti-Src antibodies, of anti-Src immunoprecipitates obtained
from lysates of VEGF-A165 (50 ng/ml for 10min)-stimulated
quiescent PAE-KDR infected with empty PINCOS vector or
PINCOS/Myc-Dgk-a. (c) Dgk enzymatic activity (upper panel),
Western blot of Dgk-a protein (central panel) and Western blot of
Src protein (lower panel), assayed in anti-Src immunoprecipitates
obtained from lysates of either control or VEGF-A165 (50 ng/ml for
10min)-stimulated quiescent PAE-KDR cells
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chemotactic gradient, to proliferate and to organize in a
network of chord-like structures on matrigel reﬂects
their behavior during the angiogenic process in vivo.
In PAE-KDR cells, the inhibition by both expression
of Dgk-a dominant-negative mutant, and cell treatment
with 1 mM R59949 severely impairs VEGF-induced
chemotaxis and DNA synthesis, as well as network
formation on matrigel, without affecting cell viability.
Thus, the data clearly demonstrate that in PAE-KDR
cells Dgk-a is activated by VEGF and that its catalytic
function is required for VEGF-induced angiogenic
signaling in vitro.
In HUVEC, R59949, which inhibits part of the
VEGF-stimulated Dgk activity, impairs VEGF-induced
chemotaxis and DNA synthesis, as well as network
organization on matrigel. The higher concentration of
the drug required to impair DNA synthesis may further
suggest that other R59949-resistant Dgk isoforms may
be involved in the transduction of VEGF proliferative
signaling in HUVEC. Alternatively, R59949 may be
sequestered by the serum required to obtain HUVEC
proliferation in cultures (De Chaffoy de Courcelles et al.,
1989). However, more direct evidence that Dgk-a is
required for in vitro angiogenesis in HUVEC primary
endothelial cells comes from the demonstration that
speciﬁc downregulation of Dgk-a expression by RNA
interference totally impairs the ability of HUVEC to
form networks on matrigel, without affecting cell
viability. The same results were obtained with three
different dsRNA, which target respectively two se-
quences at the N-terminal of the Dgk-a and a sequence
next to the ATP-binding site. The three sequences do
not feature any homology with other Dgk isoforms or
other proteins.
In summary, these experiments strongly suggest that
activation of Dgk-a is required for angiogenic signaling
in both PAE and HUVEC endothelial cells, although
the possibility that in HUVEC, which express a low level
of the a-isoform, other Dgk isoform may also be
involved in VEGF signaling should be taken into
account.
Dgk-a does not contain any domain suggesting a
direct interaction with tyrosine kinase receptors, and
indeed does not associate with either VEGFR-2 or
HGF-R (data not shown). However, a Dgk activity is
upregulated upon expression of v-Src in ﬁbroblasts
(Sugimoto et al., 1984); we and others have recently
shown that Src stimulates Dgk-a activity in vitro and
mediates HGF- and IL-2-stimulated Dgk-a activation in
intact cells (Cutrupi et al., 2000; Cipres et al., 2003).
Here, we reported that in both PAE-KDR and
HUVEC, the VEGF-induced stimulation of Dgk
activity is blunted by cell treatment, respectively, with
PP2 and PP1, two Src family-speciﬁc inhibitors that do
not affect Dgk activity in vitro (data not shown). These
data imply that even if other Dgk isoforms are also
stimulated by VEGF in these cells, their activation is
completely Src family kinase dependent. Indeed, very
recent data indicate that Dgk-a associates with Src upon
GnRH stimulation of pituitary cells (Davidson et al.,
2004). In addition, in PAE-KDR cells, we were able to
show that VEGF stimulation induces the formation of a
complex between Dgk-a and Src, but not between Dgk-a
and the activated receptor, as Dgk-a does not co-purify
in antireceptor immunoprecipitates (data not shown).
This may depend on the low stoichiometry of the Src/
Dgk-a complex, that is, only a small fraction of
receptor-associated Src forms a ternary complex with
Dgk-a. Alternatively, receptor-activated Src may come
off the complex with the receptor and may associate
with Dgk-a. Indeed according to current models of its
function, Src is recruited to the active receptor through
its SH2 domain, switches to the active open conforma-
tion, allowing complex formation with its substrates, for
instance p130Cas and FAK, their processive phosphor-
ylation and establishing a more stable complex with
them through its SH2 domain, excluding the receptor
(Nakamoto et al., 1996; Thomas et al., 1998; Scott and
Miller, 2000; Pellicena and Miller, 2001).
Although these data indicate Dgk-a as a putative
substrate of Src tyrosine kinase activity, no tyrosine
phosphorylation of Dgk-a could be detected upon
VEGF-A stimulation of either PAE-KDR or HUVEC.
However, tyrosine phosphorylation of Dgk-a was
previously shown in PAE cells upon treatment with
sodium pervanadate, and in COS cells upon coexpres-
sion of both Src and Dgk-a (Cutrupi et al., 2000). In
both cases, tyrosine phosphorylation correlates with an
increase of Dgk-a enzymatic activity. We speculate that
either tyrosine phosphorylation of Dgk-a occurs at very
low stoichiometry or is a transient event leading to the
switch of Dgk-a to an active conformation. Alterna-
tively, Src may induce tyrosine phosphorylation
of a regulator of Dgk-a. Indeed recent ﬁndings indicate
that PI(3,4,5)P3, the lipid product of PI 3-kinase,
binds and stimulates Dgk-a activity and that active
Lck stimulates Dgk-a in a PI 3-kinase-dependent
manner (Cipres et al., 2003). Therefore, it is likely that
multiple mechanisms may participate in the regulation
of Dgk-a. The identiﬁcation of the molecular determi-
nants of the physical and functional interactions
between the two proteins will shed light on such
mechanisms.
VEGF-A-induced angiogenesis, both in vitro and
in vivo, requires Src function: Src is required for
VEGF-A-induced chemotaxis and proliferation of en-
dothelial cells in vitro (Abu-Ghazaleh et al., 2001), while
genetic evidences in vivo indicate that deletion of either
Src or Yes gene in mice impairs VEGF-dependent
increase of endothelial permeability, that is, edema
formation (Eliceiri et al., 2002). Furthermore, retroviral-
mediated overexpression of Src dominant negative in a
subcutaneous model of angiogenesis severely impairs
neo-vascularization in vivo (Eliceiri et al., 1999). Thus,
the demonstration that VEGF-induced stimulation of
Dgk activity depends on Src activity, and that Dgk-a is
required for VEGF-A-induced angiogenetic responses
in vitro suggest that it may act as a crucial Src effector
in VEGF angiogenic signaling in endothelial cells. In
addition, at least in HUVEC, the involvement of other
Src-regulated Dgk isoforms in VEGF signaling is not
ruled out.
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The signaling pathways downstream to Dgk-a have
not been extensively investigated yet. Dgk enzymes
phosphorylate DG to generate PA. Indeed VEGF-A
stimulates PLC-g-mediated hydrolysis of PI(4,5)P2 to
generate DG, which then leads to activation of PKC
(Matsumoto and Claesson-Welsh, 2001). PKC-a and -b
isoforms are required for VEGF-stimulated cell prolif-
eration and migration in vitro, as well as for neovascu-
larization in vivo (Wellner et al., 1999; Wang et al.,
2002).
In some cell signaling system, activation of Dgk-a,
which removes DG to generate PA, contributes to
terminate DG-mediated signaling, while its inhibition
results in the accumulation of DG, leading to sustained
DG-mediated signaling. However, in endothelial cells,
the increased activity of PKCa, which indeed is activated
by VEGF-A in a DG-mediated manner, is expected to
enhance rather than inhibit VEGF-A-induced angio-
genic response (Wellner et al., 1999; Matsumoto and
Claesson-Welsh, 2001; Wang et al., 2002). Conversely,
the role of activation of Dgk-a in VEGF-A angiogenic
signaling may consist in the generation of PA-mediated
signals. The role of PA in VEGF-A signaling still
remains to be investigated. In vitro, PA is a regulator of
several signaling proteins, some of which are involved in
VEGF-A signaling (English, 1996; Gomez-Cambronero
and Keire, 1998; Topham and Prescott, 1999). For
instance, VEGF-A activates PKCz, which is positively
regulated by PA and Src tyrosine phosphorylation
(Limatola et al., 1994; Seibenhener et al., 1999).
Similarly, VEGF-A activates Raf, which is regulated
by PA in vitro and in intact cells (Andresen et al., 2002).
Activation of both PKCz and Raf is required for
VEGF-induced angiogenic signaling (Matsumoto and
Claesson-Welsh, 2001). Among other putative targets of
PA in vitro, Rho-GDI and PI(4)P 5-kinase might play a
role in VEGF-A signaling, respectively, by mediating
Rac activation (Del Pozo et al., 2002; Zeng et al., 2002)
and by participating in the dynamic recruitment of focal
adhesion proteins required for cell movement (Jenkins
et al., 1994; Di Paolo et al., 2002). In addition, both in
vitro and in intact cells, PA also regulates activation of
mTor, a serine kinase involved in the transduction of
growth factor-stimulated proliferative signaling
(Fang et al., 2001). However, the role of mTor in
VEGF-A signaling has not been investigated. Alterna-
tively, PA generated through activation of Dgk-a
may be further metabolized to lysosphosphatidic
acid (LPA), through a phospholipase A2. Then LPA,
through an autocrine loop, may stimulate its receptor(s),
edg.2 and -4, whose expression has been reported
in endothelial cells (Panetti, 2002). Indeed, exogenously
added LPA stimulates endothelial cell proliferation
and cell matrix-adhesion dependent cell migration
(Panetti, 2002). Interestingly, in prostate carcinoma,
bombesin, a growth factor for these cells, has
been shown to activate an LPA autocrine circuit,
which is required for bombesin signaling (Xie et al.,
2002). However, no evidence of growth factor-stimu-
lated synthesis of LPA has been reported in endo-
thelial cells.
Finally we provided evidence indicating that Dgk-a is
an essential component of VEGF-A signal transduction,
which is required to convey both chemotactic and
proliferative signals downstream from Src. Because
tumor cells produce a wide array of angiogenic factors,
it has been suggested that successful strategies to block
angiogenesis in cancer patients may repress the ability of
endothelial cells to participate in the angiogenic process.
As Dgk-a activity is required for angiogenesis and quite
speciﬁc inhibitors are available, Dgk-a may represent a
new and promising target for pharmaceutical control of
angiogenesis.
Materials and methods
Cells culture, reagents and antibodies
Porcine aortic endothelial cell line (PAE), a cell line derived
from porcine aortic endothelium, and PAE-KDR, a PAE-
derived cell line stably expressing VEGFR-2, were a kind gift
of Waltenberger (Waltenberger et al., 1994), and were cultured
in Ham’s F12 supplemented with 10% FCS, 2mM glutamine,
100U/ml penicillin and 50mg/ml streptomycin (Life Technol-
ogies). Human endothelial cells from umbilical cord veins
(HUVEC) were prepared and characterized as previously
described, and were grown in M199 medium (BioWhittaker,
Walkersville, MD, USA) supplemented with 20% FCS (Life
Technologies), endothelial cell growth factor (100 mg/ml)
(Sigma Chemical Co., St Louis, MO, USA) and porcine
heparin (Sigma) (100mg/ml). HUVEC were used at second
passage and grown on a plastic surface coated with porcine
gelatin (Sigma), otherwise speciﬁed. Recombinant VEGF-A165
was purchased from R&D systems, and R59949, PP1 and PP2
were from Alexis. Anti-Src antibodies (N-16 for immunopre-
cipitation and SRC-2 for Western blotting) were from Santa
Cruz Biotechnology, and 4G10 antiphosphotyrosine and 9E10
anti-myc tag antibodies were from UBI. Anti-Dgk-a anti-
bodies were a mix of monoclonal obtained as described
(Schaap et al., 1993). Anti-VEGFR-2 antibodies were from
Santa Cruz Biotechnologies. ECL and secondary antibodies
were from Perkin-Elmer. PINCOS, PINCOS/Myc-Dgk-a,
PINCOS/Myc-Dgk-a-K and the PHOENIX retroviral system
were previously described (Cutrupi et al., 2000). Unless
speciﬁed, all other reagents were from Sigma-Aldrich.
Infection with retroviral vectors
Phoenix cells obtained by G Nolan (Swift et al., 1999) were
transiently transfected by calcium phosphate (Cell Phect
Transfection kit, Amersham-Pharmacia) with 20mg PINCOS,
PINCOS/Myc-Dgk-a or 20mg PINCOS/Myc-Dgk-a-K in
growth media containing chloroquin (25 mM). Cells were
incubated for 8 h at 371C (5% CO2) and the precipitate was
removed by washing with PBS. Then, cells were incubated with
DMEM containing 10% FCS for 72 h; the retroviral super-
natant was collected, the debris removed by 1500 g centrifuga-
tion, ﬁltered by a 0.8 pore ﬁlter, and supplemented with
Polybrene (8 mg/ml). Log-phase growing PAE-KDR cells were
infected by addition of 5ml retroviral supernatant. Following
16 h from infection, cells were placed into 10% FCS medium
for 48 h and serum starved overnight in 0.5% FCS prior to
further experimental manipulations. PINCOS-infected cells
express both GFP and the protein of interest. Efﬁciency of
infection was about 70% as measured by FACS analysis of
GFP expression.
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Preparation of cell lysate, homogenates, immunoprecipitation
and Western blotting
Subconﬂuent PAE-KDR cultures were made quiescent by 16 h
serum starvation. Subconﬂuent HUVEC cultures were made
quiescent by incubating for 16 h in 5% FCS. Following cell
stimulation, the cell lysates were prepared in buffer A (25mM
Hepes pH 8, 10% glycerol, 150mM NaCl, 5mM EDTA, 2mM
EGTA, 1mM ZnCl2, 50mM ammonium molibdate, supplied
before use with 1mM sodium orthovanadate, 10mM NaF,
0.5mM dithiothreitol, 0.2mM phenylmethylsulfonyl ﬂuoride,
1 mg/ml leupeptin, 1 mg/ml aprotinin and 1mg/ml pepstatin,
1 mg/ml soybean trypsin inhibitor) supplemented with 1% NP-
40, as described previously (Cutrupi et al., 2000). Where
indicated, cell extracts were prepared by collecting the cells
with a rubber scraper in buffer A and homogenizing them in
syringe–needle in buffer A. Protein concentration was deter-
mined by the BCA method (Pierce). Immunoprecipitation,
SDS–PAGE and Western blots were performed as described
previously (Cutrupi et al., 2000).
Dgk-a assay
Dgk-a was assayed in the immunoprecipitates essentially as
described (Schaap et al., 1993): immunocomplexes were
incubated for 5min at 301C with 1mg/ml diolein (Fluka),
1mM ATP, 30mCi-[g32P]ATP (Amersham), 10mM MgCl2,
1mM ZnCl2, 1mM EGTA in 25mM Hepes pH 8, and the
reaction stopped with 50 ml of 1M HCl and 100 ml of
chloroform :methanol 1 : 1. Lipids were then extracted, and
separated by TLC in chloroform :methanol :water : 25% ammo-
nium hydroxide (60 : 47 : 11 : 4). TLC was exposed on a
autoradiographic ﬁlm (Kodak Biomax), [32P]PA was identiﬁed
by co-migration with nonradioactive PA standards stained by
incubation in an iodine chamber. PA spots were quantiﬁed using
phosphor imager (Biorad). Dgk activity in homogenates (1–5ml)
was assayed as described above, except that ATP was 5mM.
Cell migration assay
For migration on gelatin, endothelial cells were seeded (1 105
cells in 50 ml suspension) in the upper chamber of a modiﬁed
Boyden chamber. The undersurface of PVDF ﬁlter (8 mm
pores, Nucleopore) was coated with 0.1% gelatin. The lower
chamber was ﬁlled with serum-free medium with or without
VEGF-A165 and incubated at 371C in air with 5% CO2 for 6h.
Where indicated, 1mM R59949 was added to the upper chamber
with the cells. Filters were then removed, stained with Diff-Quik
(Baxter Diagnostic AG) and the cells of ﬁve ﬁelds were counted
at the inverted microscope with a high-power oil immersion
objective (Zeiss). For migration on collagen I, endothelial cells
were seeded (1 105 cells in 50ml suspension) in the upper
chamber of a chemotox chamber (Nuroprobe), coated with
20ng/ml collagen I. The lower chamber was ﬁlled with serum-
free medium with or without VEGF-A165 and incubated at 371C
in air with 5% CO2 for 6h. Filters were then removed, stained
with crystal violet and the cells of ﬁve ﬁelds were counted at the
inverted microscope (Zeiss axiovert).
Cell proliferation assay
PAE KDR cells were plated and after 6 h treated as indicated
for 24 h. HUVEC cells were plated and after 24 h treated as
indicated for additional 48 h. BrdU incorporation was
measured with ‘Cell Proliferation ELISA Biotrak System’
from Amersham-Pharmacia as suggested by the manufacturer.
Matrigel morphogenetic assay
Matrigel (Collaborative Biomedical Products, Becton Dick-
inson, Milan, Italy; not puriﬁed from contaminant growth
factors; 0.2ml). was added to each well of a 48-well plate and
incubated at 371C for 30min to allow gel formation.
Endothelial cells (2 104/well) were plated onto Matrigel.
After 48 h incubation in the presence or absence of the
indicated treatments in 5% CO2 humidiﬁed atmosphere at
371C, the three-dimensional organization of the cells was
examined under an inverted phase contrast photomicroscope
(DM-IBM model; Leica Microsystems, Wetzlar, Germany)
and then photographed. Not puriﬁed matrigel allows sponta-
neous in vitro angiogenesis (Marconcini et al., 1999).
RNA interference
HUVEC were transfected with siPORT lipid transfection
agent (Ambion) as suggested by the manufacturer. Cell
transfection procedures must be optimized for each HUVEC
preparation using Silencer siRNA Transfection KIT (Am-
bion). siRNA used were chemically synthesized as double-
strand RNA (Ambion). The sequence was designed using
Cenix bioscience algorithm, which considers Tm, nucleotide
content of the 30 overhangs, nucleotide distribution over the
length of the siRNA, and presence and location of mismatches
to off target genes. A key step in the algorithm is a stringent
analysis of each siRNA sequence to maximize the target
speciﬁcity. Sequences were as follows: DGK1 sense GGUCA
GUGAUGUCCUAAAGTT, antisense CUUUAGGACAU
CACUGACCTT (target AAGGTCAGTGATGTCCTAAAG);
DGK2 sense GGAUGGCGAGAUGGCUAAATT, antisense
UUUAGCCAUCUCGCCAUCCTC (target AAGGATGGC
GAGATGGCTAAA); and DGK3 sense GGAUUUAGA-
GAUGAGUAAATT, antisense UUUACUCAUCUCUAAA
UCCTT (target AAGGATTTAGAGATGAGTAAA). A GA
PDH scramble siRNA was used as negative control (provided
with Silencer siRNA Transfection KIT from Ambion).
Reproducibility and data analysis
All the experiments shown are representative of three or more
independent experiments with similar results. In Figures 3c
and 7a, data are mean7s.e.m. of ﬁve independent experiments
normalized for control.
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